Description
The PEARL Study, a first of its kind, real-world prospective observational study conducted in Nigeria, evaluated the usage patterns, safety, and efficacy of Rosuvastatin in patients with Dyslipidemia. The study included 221 patients, mostly middle-aged, who were treated with 5mg, 10mg, or 20mg doses of Rosuvastatin across three visits. Results were assessed based on:
- Significant improvements in lipid profiles, with reductions in LDL-C, total cholesterol and triglycerides
- Increase in HDL
- Reduction in blood pressure
- Patient adherence to Rosuvastatin over the study duration
This overview presents these findings in detail, along with physician assessments highlighting Rosuvastatin’s safety, efficacy, and value in long-term dyslipidemia management.